A special message from Dr. Michael Liss and the AUA Quality Improvement and Patient Safety Committee. On July 26, 2016, the U.S. Food and Drug Administration (FDA) approved changes to the labels of flouroquinolone antibacterial drugs for systemic...
They do business with integrity and rational thinking. Overall, it's an excellent place to work, with products that are winning in the marketplace.